VANTRELA ER Drug Patent Profile
✉ Email this page to a colleague
When do Vantrela Er patents expire, and what generic alternatives are available?
Vantrela Er is a drug marketed by Teva Branded Pharm and is included in one NDA. There are three patents protecting this drug.
This drug has thirty-three patent family members in thirteen countries.
The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydrocodone bitartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vantrela Er
A generic version of VANTRELA ER was approved as hydrocodone bitartrate by ALVOGEN on January 21st, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VANTRELA ER?
- What are the global sales for VANTRELA ER?
- What is Average Wholesale Price for VANTRELA ER?
Summary for VANTRELA ER
International Patents: | 33 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
DailyMed Link: | VANTRELA ER at DailyMed |
US Patents and Regulatory Information for VANTRELA ER
VANTRELA ER is protected by three US patents.
Patents protecting VANTRELA ER
Abuse resistant drug formulation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Abuse resistant drug formulation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Abuse resistant drug formulation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-001 | Jan 17, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-003 | Jan 17, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-002 | Jan 17, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-004 | Jan 17, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-003 | Jan 17, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Teva Branded Pharm | VANTRELA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 207975-005 | Jan 17, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VANTRELA ER
When does loss-of-exclusivity occur for VANTRELA ER?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Canada
Patent: 63172
Patent: PREPARATION MEDICAMENTEUSE EMPECHANT L'UTILISATION ABUSIVE (ABUSE RESISTANT DRUG FORMULATION)
Estimated Expiration: ⤷ Sign Up
Patent: 99142
Patent: FORMULATION MEDICAMENTEUSE CONTRE L'ABUS (ABUSE RESISTANT DRUG FORMULATION)
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 15005
Estimated Expiration: ⤷ Sign Up
Patent: 16598
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 73795
Estimated Expiration: ⤷ Sign Up
Patent: 00593
Estimated Expiration: ⤷ Sign Up
Patent: 92341
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 73795
Patent: PRÉPARATION MÉDICAMENTEUSE EMPÊCHANT L'UTILISATION ABUSIVE (ABUSE RESISTANT DRUG FORMULATION)
Estimated Expiration: ⤷ Sign Up
Patent: 00593
Patent: FORMULATION MÉDICAMENTEUSE CONTRE L'ABUS (ABUSE RESISTANT DRUG FORMULATION)
Estimated Expiration: ⤷ Sign Up
Patent: 92341
Patent: Préparation médicamenteuse empêchant l'utilisation abusive (Abuse resistant drug formulation)
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 34775
Patent: 抗濫用藥物製劑 (ABUSE RESISTANT DRUG FORMULATION)
Estimated Expiration: ⤷ Sign Up
Patent: 93567
Patent: 抗濫用藥物配方 (ABUSE RESISTANT DRUG FORMULATION)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 27128
Estimated Expiration: ⤷ Sign Up
Patent: 32012
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 57032
Estimated Expiration: ⤷ Sign Up
Patent: 30572
Estimated Expiration: ⤷ Sign Up
Patent: 11504455
Estimated Expiration: ⤷ Sign Up
Patent: 11517654
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 6861
Patent: FORMULACION DE FARMACO RESISTENTE AL ABUSO. (ABUSE RESISTANT DRUG FORMULATION.)
Estimated Expiration: ⤷ Sign Up
Patent: 09002757
Patent: FORMULACION DE FARMACO RESISTENTE AL ABUSO. (ABUSE RESISTANT DRUG FORMULATION.)
Estimated Expiration: ⤷ Sign Up
Patent: 10002780
Patent: FORMULACION DE FARMACO RESISTENTE AL ABUSO. (ABUSE RESISTANT DRUG FORMULATION.)
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 73795
Estimated Expiration: ⤷ Sign Up
Patent: 00593
Estimated Expiration: ⤷ Sign Up
Patent: 92341
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 73795
Estimated Expiration: ⤷ Sign Up
Patent: 92341
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 73795
Estimated Expiration: ⤷ Sign Up
Patent: 92341
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 52033
Estimated Expiration: ⤷ Sign Up
Patent: 43802
Estimated Expiration: ⤷ Sign Up
Patent: 11794
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VANTRELA ER around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 2692341 | ⤷ Sign Up | |
Cyprus | 1116598 | ⤷ Sign Up | |
Denmark | 2200593 | ⤷ Sign Up | |
Spain | 2611794 | ⤷ Sign Up | |
Hungary | E027128 | ⤷ Sign Up | |
Canada | 2699142 | FORMULATION MEDICAMENTEUSE CONTRE L'ABUS (ABUSE RESISTANT DRUG FORMULATION) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |